Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 593


Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.

Kong D, Okamura M, Yoshimi H, Yamori T.

Eur J Cancer. 2009 Mar;45(5):857-65. doi: 10.1016/j.ejca.2008.12.007. Epub 2009 Jan 12.


CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.


Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.

Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Broggini M, Iacobelli S, Potter BV, Innocenti P, Falasca M.

Cancer Res. 2005 Sep 15;65(18):8339-49.


Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Sci. 2008 Oct;99(10):2083-96. doi: 10.1111/j.1349-7006.2008.00948.x.


Anti-tumor actions of major component 3'-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Lett. 2008 Jun 28;265(1):84-97. doi: 10.1016/j.canlet.2008.02.009. Epub 2008 Mar 20.


Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.

Nakamura S, Chikaraishi Y, Tsuruma K, Shimazawa M, Hara H.

Exp Eye Res. 2010 Jan;90(1):137-45. doi: 10.1016/j.exer.2009.09.022. Epub 2009 Oct 13.


In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells.

Zhao W, Guo W, Zhou Q, Ma SN, Wang R, Qiu Y, Jin M, Duan HQ, Kong D.

Int J Mol Sci. 2013 Jun 28;14(7):13577-91. doi: 10.3390/ijms140713577.


Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.

Fernand VE, Losso JN, Truax RE, Villar EE, Bwambok DK, Fakayode SO, Lowry M, Warner IM.

Chem Biol Interact. 2011 Jul 15;192(3):220-32. doi: 10.1016/j.cbi.2011.03.013. Epub 2011 Mar 30.


Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.

Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M.

Br J Cancer. 2001 Dec 14;85(12):2010-6.


SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.

Cancer Res. 2000 Aug 1;60(15):4152-60.


Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.

Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD.

Mol Cancer Ther. 2003 Sep;2(9):845-54.


1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo.

Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE.

Circ Res. 2000 Aug 4;87(3):214-20.


Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.

He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.

Cancer Sci. 2011 Jan;102(1):219-25. doi: 10.1111/j.1349-7006.2010.01778.x. Epub 2010 Nov 19.


mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.


Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.

Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE.

Lab Invest. 2009 Jan;89(1):38-46. doi: 10.1038/labinvest.2008.106. Epub 2008 Nov 10.


Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.


Supplemental Content

Support Center